Victrelis (boceprevir) has been approved by the FDA for adults with hepatitis C who have either never been treated with medications before or have not responded well to drug therapy. The FDA (Food and Drug Administration) approval is for Victrelis use alongside peginterferon alfa and ribavirin. The FDA evaluated two Phase III trials involving 1,500 adult patients with chronic hepatitis C. In both cases over 60% of patients administered Victrelis alongside the other two medications had no detectable hepatitis C virus 24 weeks after treatment stopped (24-week virologic response)... 
More...
More...